Evidence map›Paper›PMID 21077276›Full record

ArticleClinical and experimental immunology2010

Anti-neutrophil cytoplasmic antibodies target sequential functional proteinase 3 epitopes in the sera of patients with Wegener’s granulomatosis.

B F Bruner, E S Vista, D M Wynn, J B Harley, J A James

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental immunology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

B F BrunerOklahoma Medical Research Foundation, Oklahoma City, 73104, USA.
E S Vista
D M Wynn
J B Harley
J A James
Oklahoma Medical Research Foundation · USUniversity of Oklahoma Health Sciences Center · US

Funding

THE EFFECTS OF ERK PATHWAY INHIBITION ON DNA METHYLATION IN SLEP20RR015577 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CENTOLA, MICHAEL B · 2000 to 2009
$21.5M
VALIDATING NOVEL GENES IMPLICATED IN LEUKOCYTE CHEMOTAXISP20RR020143 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI KAUFMAN, KENNETH M · 2004 to 2011
$21.0M
Program Project in the Genetics of SLEP01AR049084 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KIMBERLY, ROBERT P. · 2002 to 2012
$12.7M
HLA GENE COMPLEMENTATION IN PRIMARY SJOGREN'S AND LUPUSR01AI024717 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI KOTTYAN, LEAH CLAIRE, WEIRAUCH, MATTHEW TYSON · 1987 to 2025
$7.8M
SNP Confirmation and High Throughput Genotyping CoreP30AR053483 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI CHAKRAVARTY, ELIZA F · 2007 to 2017
$6.7M
Pre-Clinical Studies to Identify SLE Therapeutic TargetsU19AI082714 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2009 to 2018
$6.2M
THROMBOCYTOPENIA AND THE GENETICS OF SEVERE LUPUSP50AR048940 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI REICHLIN, MORRIS · 2002 to 2006
$5.8M
Genetic Linkage in LupusR37AI024717 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI HARLEY, JOHN BARKER · 2005 to 2014
$4.2M
Science in a Culture of MentoringP30GM103510 · NIGMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2012 to 2016
$3.9M
Science in a Culture of MentoringP30RR031152 · NCRR · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2010 to 2011
$2.4M
Fine specificity of scleroderma autoantibodiesR01AR048045 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 2001 to 2005
$1.6M
ROLE OF ANTIPROTEINASE 3 IN WEGENER'S VASCULOPATHYR01AI047575 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI JAMES, JUDITH A · 1999 to 2003
$1.2M
NCRR NIH HHS P20 RR015577NCRR NIH HHS P20 RR020143NCRR NIH HHS P30 RR031152NCRR NIH HHS RR015577NCRR NIH HHS RR020143NIAID NIH HHS AI082714NIAID NIH HHS AI47575NIAID NIH HHS R01 AI024717NIAID NIH HHS R01 AI047575NIAID NIH HHS R37 AI024717NIAID NIH HHS U19 AI082714NIAMS NIH HHS AR053483NIAMS NIH HHS AR45451NIAMS NIH HHS AR48045NIAMS NIH HHS AR48940NIAMS NIH HHS AR49084NIAMS NIH HHS P01 AR049084NIAMS NIH HHS P30 AR053483NIAMS NIH HHS P50 AR048940NIAMS NIH HHS R01 AR045451NIAMS NIH HHS R01 AR048045NIGMS NIH HHS P30 GM103510
6 · The paper itself

Abstract

Many patients with Wegener’s granulomatosis (WG) have anti-neutrophil cytoplasmic antibodies (c-ANCA). Aside from being a diagnostic marker, these autoantibodies may play roles in disease pathogenesis. Proteinase 3 (PR3) is the primary target of c-ANCA in WG patient sera. Of 60 c-ANCA-positive patients, 10 patients were selected for detailed humoral epitope analysis, contingent upon serum availability, using samples with positive levels of anti-PR3 by enzyme-linked immunosorbent assay (ELISA). Sequential epitope specificities of anti-PR3 antibodies detected by screening the maximally overlapping solid-phase octapeptides of PR3 showed seven major common antigenic targets bound by WG patient sera. These include novel and previously identified sequential PR3 epitopes bound by c-ANCA. B cell epitope prediction algorithms identified all or part of the seven defined epitopes. Several epitopes share sequence and structural proximity with functional sites, including the catalytic triad and proposed binding sites of other potential proteins [PR3 complementary peptide and soluble endothelial protein C receptor (sEPCR)]. Epitope 4 (VVLGAHNVRTQ) had the highest binding prevalence (90%) and epitope 2 (AQPHSRPYMAS) has the highest average reactivity of the antigenic regions. Epitope 4 includes the interaction site between sEPCR and PR3 which may serve as an important interaction to down-regulate inflammation. Epitopes 3, 5 and 7 are in direct proximity to amino acids that form the catalytic triad of the protein. c-ANCA targets both unique and previously known sequential PR3 peptides. This information may prove useful in understanding anti-PR3-mediated disease pathogenesis in systemic vasculitides.

Indexed as

AdolescentAdultAgedAged, 80 and overAlgorithmsAmino Acid SequenceAntibodies, Antineutrophil CytoplasmicEpitopes, B-LymphocyteFemaleGranulomatosis with PolyangiitisHumansIsoelectric PointMaleMiddle AgedModels, MolecularMyeloblastinAntibodies, Antineutrophil CytoplasmicEpitopes, B-LymphocyteMyeloblastinPeptide Fragments

Identifiers

PMID21077276
PMCPMC2996593
OpenAlexW1953462100

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.